Photodynamic Therapy with Verteporfin in Subfoveal Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy

Archives of Ophthalmology

Volumn 122, Issue 1, 2004, Pages 37-41

  Ergun, Erdem ^a   Tittl, Michael ^b   Stur, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b DANUBE HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; FLUORESCEIN; INDOCYANINE GREEN;

ADULT; AGED; ARTICLE; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; NEOVASCULARIZATION (PATHOLOGY); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINOPATHY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; CHOROID DISEASES; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSPECTIVE STUDIES; RETINAL DISEASES; SAFETY; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 0347985352     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.1.37     Document Type: Article

References (47)

1. Maguire JI. Central serous chorioretinopathy. In: Tasman WS, ed. Clinical Decisions in Medical Retinal Disease. St Louis, Mo: Mosby-Year Book; 1994.
2. Frederick AR. Multifocal and recurrent serous choroidopathy (MARC) syndrome: a new variety of idiopathic central serous chorioretinopathy. Doc Ophthalmol. 1984;56:203-235.
3. Jalkh AE, Jabbour N, Avila MP, et al. Retinal pigment epithelium decompression, I: clinical features and natural course. Ophthalmology. 1984;91:1544-1548.
4. Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996;103:2070-2080.
5. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials: TAP Report 1. Arch Ophthalmol. 1999;117:1329-1345.
6. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials: TAP Report 2. Arch Ophthalmol. 2001;119:198-207.
7. Blumenkranz MS, Bressler NM, Bressler SB, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials. Arch Ophthalmol. 2002;120:1307-1314.
8. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: VIP Report 2. Am J Ophthalmol. 2001; 131:541-560.
9. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial: VIP Report 1. Ophthalmology. 2001;108:841-852.
10. Spaide RF, Freund KB, Slakter J, et al. Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina. 2002;22:545-549.
11. Saperstein DA, Rosenfeld PJ, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled prospective case series. Ophthalmology. 2002;109:1499-1505.
12. Dantas MA, Slakter JS, Negrao S, et al. Photodynamic therapy with verteporfin in malattia leventinese. Ophthalmology. 2002;109:296-301.
13. Potter MJ, Szabo SM, Chan EY, Morris AH. Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveal retinal telangiectasis. Am J Ophthalmol. 2002;133:149-151.
14. Wang LK, Kansai S, Pulido JS. Photodynamic therapy for the treatment of choroidal neovascularization secondary to rubella retinopathy. Am J Ophthalmol. 2002; 134:790-792.
15. Spaide RF, Martin ML, Slakter J, et al. Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy. Am J Ophthalmol. 2002; 134:62-68.
16. Farah ME, Costa RA, Muccioli C, Gula TA, Belfort R. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 2002;134:137-139.
17. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol. 1991;109:1109-1114.
18. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol. 1993;111:1200-1209.
19. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1996;114:400-412.
20. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1220-1231.
21. Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol. 1986;104:503-512.
22. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol. 1994;112:480-488.
23. Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina. 1987; 7:111-131.
24. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002;22:6-18.
25. Loo RH, Scott IU, Flynn HW, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19-24.
26. Bujaborua D. Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand. 2001;79:417-421.
27. Shanmugam MP, Bhende M. Retinal pigment epithelial tears associated with idiopathic central serous chorioretinopathy. Indian J Ophthalmol. 2000;48:315-317.
28. Brancato R, Scialdone A, Pece A, Coscas G, Binaghi M. Eight-year follow-up of central serous chorioretinopathy with and without laser treatment. Graefes Arch Clin Exp Ophthalmol. 1987;225:166-168.
29. Piccolino FC. Laser treatment of eccentric leaks in central serous chorioretinopathy resulting in disappearance of untreated juxtafoveal leaks. Retina. 1992;12: 96-102.
30. Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol. 1996;114:689-692.
31. Robertson DM. Argon laser photocoagulation treatment in central serous chorioretinopathy. Ophthalmology. 1986;93:972-974.
32. Schatz H, Yannuzzi LA, Gitter KA. Subretinal neovascularization following argon photocoagulation treatment for central serous chorioretinopathy: complication or misdiagnosis. Trans Am Acad Ophthalmol Otolaryngol. 1977;83:893-906.
33. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol. 1994;112:1057-1062.
34. Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of central serous chodoretinopathy in older adults. Retina. 1996;16:203-213.
35. Carvalho-Recchia CA, Yannuzzi LA, Negrao S, Spaide RF, Freund KB. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002;109:1834-1837.
36. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47:431-438.
37. Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128:63-68.
38. Quillen DA, Gass DM, Brod RD, et al. Central serous chorioretinopathy in women. Ophthalmology. 1996;103:72-79.
39. Sibayan SA, Kobuch K, Spiegel D, et al. Epinephrine, but not dexamethasone, induces apoptosis in retinal pigment epithelium cells in vitro: possible implications on the pathogenesis of central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2000;238:515-519.
40. Bernasconi P, Messmer E, Bernasconi A, Tholen A. Assessment of the sympathovagal interaction in central serous chorioretinopathy measured by power spectral analysis of heart rate variability. Graefes Arch Clin Exp Ophthalmol. 1998; 236:571-576.
41. Blinder K, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136:407-418.
42. Rogers AH, Duker JS, Nichols N, Baker BJ. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology. 2003;110:1315-1320.
43. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23:288-298.
44. Cooper BA, Thomas MA. Submacular surgery to remove choroidal neovascularization associated with central serous chorioretinopathy. Am J Ophthalmol. 2000;130:187-191.
45. Yannuzzi LA, Freund KB, Goldbaum M, et al. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy. Ophthalmology. 2001;107: 767-777.
46. Lafaut BA, Salati C, Priem H, De Laey JJ. Indocyanine green angiography is of value for the diagnosis of central serous chorioretinopathy in elderly patients. Graefes Arch Clin Exp Ophthalmol. 1998;236:513-521.
47. Slakter JS, Yannuzzi LA, Guyer DR, Sorenson JA, Orlock DA. Indocyanine-green angiography. Curr Opin Ophthalmol. 1995;6:25-32.